Position in DSGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$2,889,334
+$2,420,119 QoQ
Shares Held
271,554
+442.9% QoQ
Ownership
0.435%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $354,986,312 across 62 Biotechnology names. DSGN ranks #42 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
484,580 | $31,318,405 | |
| 2 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
1,199,598 | $29,702,046 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
137,099 | $14,450,234 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
360,490 | $13,875,260 | |
| 5 | NAMS |
NewAmsterdam Pharma Co N.V.
|
408,492 | $13,075,828 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
304,615 | $12,279,030 | |
| 7 | CLDX |
Celldex Therapeutics, Inc.
|
352,302 | $11,175,019 | |
| 8 | APGE |
Apogee Therapeutics, Inc.
|
122,669 | $10,325,049 |
All Filings in DSGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,889,334 | 271,554 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $469,215 | 50,023 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $221,464 | 29,411 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $50,583 | 15,010 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $55,518 | 14,383 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $88,021 | 14,266 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||